首页 > 最新文献

Biomedica : revista del Instituto Nacional de Salud最新文献

英文 中文
Loneliness as a predictor of mortality in cancer patients, a cohort study [孤独是癌症患者死亡率的预测因素,一项队列研究]。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7150
Adriana Valdelamar, Fernando De La Hoz, Ricardo Sánchez

Introduction. Some studies have indicated that loneliness may be associated with an increased risk of mortality in cancer patients, as it can weaken treatment response and the immune system, and promote harmful behaviors, worsening the prognosis and increasing the likelihood of death. Addressing loneliness in public health is essential to provide social support and improve outcomes in cancer patients.Objective. To obtain an estimator of the unwanted loneliness-mortality association.Materials and methods. We followed a prospective cohort of 400 patients for two years (exposure=loneliness levels; outcome=mortality; sociodemographic and clinical control variables were included). A parametric survival model (log normal) was used.Results. The cohort had a median survival of 20.2 months and a mortality rate of 3.2 deaths/100 patient-months (95% CI: 2.8 to 3.7). The survival model found the following time ratios (TR): moderate level/low level: TR=0.55; 95% CI: 0.39 to 0.77; moderately high level/low level: TR=0.62; 95% CI: 0.41 to 0.93; high level/low level: TR=1.17; 95% CI: 0.31 to 4.42.Conclusion. Compared to patients with low levels of loneliness, patients with moderate or moderately high levels reach death more quickly (statistically significant TRs, adjusted for the effect of other variables in the model); this highlights the need for interventions to mitigate loneliness and promote social support in patients having cancer.

导言。一些研究表明,孤独可能与癌症患者死亡风险的增加有关,因为孤独会削弱对治疗和免疫系统的反应,并助长有害行为,这可能会恶化预后,增加这些患者死亡的可能性。在公共卫生中解决孤独问题对于为癌症患者提供社会支持和改善预后至关重要。目标。估算癌症患者不必要的孤独感与死亡率之间的关系。材料和方法。对 400 名患者进行为期两年的前瞻性队列随访(暴露=孤独程度;结果=死亡时间)。社会人口学变量和临床控制变量也包括在内。采用参数生存模型(对数正态)。研究结果组群的中位生存期为 20.2 个月,死亡率为每 100 个患者月 3.2 例死亡(95% CI 2.8 至 3.7)。生存模型中发现了以下生存比(RT):中低水平:RT=0.55,95% CI 0.39 至 0.77;中高水平-低水平:RT=0.62,95% CI 0.41 至 0.93;高水平-低水平:RT=1.17,95% CI 0.31 至 4.42。结论与低度孤独感患者相比,中度或中度高度孤独感患者的死亡速度更快(在对模型中其他变量的影响进行调整后,RT具有显著的统计学意义)。这表明,减轻癌症患者孤独感和促进社会支持的干预措施是有用的。
{"title":"Loneliness as a predictor of mortality in cancer patients, a cohort study","authors":"Adriana Valdelamar, Fernando De La Hoz, Ricardo Sánchez","doi":"10.7705/biomedica.7150","DOIUrl":"10.7705/biomedica.7150","url":null,"abstract":"<p><p>Introduction. Some studies have indicated that loneliness may be associated with an increased risk of mortality in cancer patients, as it can weaken treatment response and the immune system, and promote harmful behaviors, worsening the prognosis and increasing the likelihood of death. Addressing loneliness in public health is essential to provide social support and improve outcomes in cancer patients.\u0000Objective. To obtain an estimator of the unwanted loneliness-mortality association.\u0000Materials and methods. We followed a prospective cohort of 400 patients for two years (exposure=loneliness levels; outcome=mortality; sociodemographic and clinical control variables were included). A parametric survival model (log normal) was used.\u0000Results. The cohort had a median survival of 20.2 months and a mortality rate of 3.2 deaths/100 patient-months (95% CI: 2.8 to 3.7). The survival model found the following time ratios (TR): moderate level/low level: TR=0.55; 95% CI: 0.39 to 0.77; moderately high level/low level: TR=0.62; 95% CI: 0.41 to 0.93; high level/low level: TR=1.17; 95% CI: 0.31 to 4.42.\u0000Conclusion. Compared to patients with low levels of loneliness, patients with moderate or moderately high levels reach death more quickly (statistically significant TRs, adjusted for the effect of other variables in the model); this highlights the need for interventions to mitigate loneliness and promote social support in patients having cancer.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"119-138"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined hyperglycemic crises in adult patients already exist in Latin America 拉丁美洲已经出现了成人患者合并高血糖危象。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.6912
Guillermo Edinson Guzmán, Veline Martínez, Sebastián Romero, María Mercedes Cardozo, María Angélica Guerra, Oriana Arias

Introduction: Diabetes mellitus is one of the most common diseases worldwide, with a high morbidity and mortality rate. Its prevalence has been increasing, as well as its acute complications, such as hyperglycemic crises. Hyperglycemic crises can present with combined features of diabetic ketoacidosis and hyperosmolar state. However, their implications are not fully understood.

Objective: To describe the characteristics, outcomes, and complications of the diabetic population with hyperglycemic crises and to value the combined state in the Latin American population.

Materials and methods: Retrospective observational study of all hyperglycemic crises treated in the intensive care unit of the Fundación Valle del Lili between January 1, 2015, and December 31, 2020. Descriptive analysis and prevalence ratio estimation for deaths were performed using the robust Poisson regression method.

Results: There were 317 patients with confirmed hyperglycemic crises, 43 (13.56%) with diabetic ketoacidosis, 9 (2.83%) in hyperosmolar state, and 265 (83.59%) with combined diabetic ketoacidosis and hyperosmolar state. Infection was the most frequent triggering cause (52.52%). Fatalities due to ketoacidosis occurred in four patients (9.30%) and combined diabetic ketoacidosis/hyperosmolar state in 22 patients (8.30%); no patient had a hyperosmolar state. Mechanical ventilation was associated with death occurrence (adjusted PR = 1.15; 95 % CI 95 = 1.06 - 1.24).

Conclusions: The combined state was the most prevalent presentation of the hyperglycemic crisis, with a mortality rate similar to diabetic ketoacidosis. Invasive mechanical ventilation was associated with a higher occurrence of death.

引言糖尿病是全球最常见的疾病之一,发病率和死亡率都很高。其发病率和急性并发症(如高血糖危象)都在不断增加。高血糖危象可表现为糖尿病酮症酸中毒和高渗状态的综合特征。目的:描述高血糖危象的特征、结果和影响:描述患有高血糖危象的糖尿病患者的特征、预后和并发症,并评估拉丁美洲人群中合并状态的价值:对 2015 年 1 月 1 日至 2020 年 12 月 31 日期间在 Valle del Lili 基金会重症监护室接受治疗的所有高血糖危象进行回顾性观察研究。采用稳健泊松回归法对死亡病例进行了描述性分析和流行率估算:317名患者确诊为高血糖危象,43名(13.56%)为糖尿病酮症酸中毒,9名(2.83%)为高渗状态,265名(83.59%)为糖尿病酮症酸中毒和高渗状态合并症。感染是最常见的诱因(52.52%)。4名患者(9.30%)因酮症酸中毒死亡,22名患者(8.30%)合并糖尿病酮症酸中毒/高渗状态;没有患者出现高渗状态。机械通气与死亡发生率相关(调整后 PR = 1.15;95 % CI 95 = 1.06 - 1.24):结论:合并状态是高血糖危象最常见的表现形式,其死亡率与糖尿病酮症酸中毒相似。侵入性机械通气与较高的死亡发生率有关。
{"title":"Combined hyperglycemic crises in adult patients already exist in Latin America","authors":"Guillermo Edinson Guzmán, Veline Martínez, Sebastián Romero, María Mercedes Cardozo, María Angélica Guerra, Oriana Arias","doi":"10.7705/biomedica.6912","DOIUrl":"10.7705/biomedica.6912","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus is one of the most common diseases worldwide, with a high morbidity and mortality rate. Its prevalence has been increasing, as well as its acute complications, such as hyperglycemic crises. Hyperglycemic crises can present with combined features of diabetic ketoacidosis and hyperosmolar state. However, their implications are not fully understood.</p><p><strong>Objective: </strong>To describe the characteristics, outcomes, and complications of the diabetic population with hyperglycemic crises and to value the combined state in the Latin American population.</p><p><strong>Materials and methods: </strong>Retrospective observational study of all hyperglycemic crises treated in the intensive care unit of the Fundación Valle del Lili between January 1, 2015, and December 31, 2020. Descriptive analysis and prevalence ratio estimation for deaths were performed using the robust Poisson regression method.</p><p><strong>Results: </strong>There were 317 patients with confirmed hyperglycemic crises, 43 (13.56%) with diabetic ketoacidosis, 9 (2.83%) in hyperosmolar state, and 265 (83.59%) with combined diabetic ketoacidosis and hyperosmolar state. Infection was the most frequent triggering cause (52.52%). Fatalities due to ketoacidosis occurred in four patients (9.30%) and combined diabetic ketoacidosis/hyperosmolar state in 22 patients (8.30%); no patient had a hyperosmolar state. Mechanical ventilation was associated with death occurrence (adjusted PR = 1.15; 95 % CI 95 = 1.06 - 1.24).</p><p><strong>Conclusions: </strong>The combined state was the most prevalent presentation of the hyperglycemic crisis, with a mortality rate similar to diabetic ketoacidosis. Invasive mechanical ventilation was associated with a higher occurrence of death.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"110-118"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes in patients with diabetes and stress hyperglycemia that developed SARS-CoV-2 infection 感染 SARS-CoV-2 的糖尿病和应激性高血糖患者的临床疗效。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7095
Karen M Fériz-Bonelo, María B Iriarte-Durán, Oscar Giraldo, Luis G Parra-Lara, Veline Martínez, María A Urbano, Guillermo Guzmán

Introduction: Diabetes and stress hyperglycemia have been related with poorer clinical outcomes in patients infected by SARS-CoV-2 and at risk for severe disease.

Objective: To evaluate clinical outcomes in three groups of patients (with diabetes, without diabetes and with stress hyperglycemia) with SARS-CoV-2 infection.

Materials and methods: A retrospective cohort study was conducted in Cali (Colombia). We included patients 18 years old or older with a diagnosis of SARS-CoV-2 infection, managed in the emergency room, hospitalization, or intensive care unit between March 2020 and December 2021. Immunocompromised patients and pregnant women were excluded. Patients were classified into three groups: without diabetes, with diabetes, and with stress hyperglycemia. A comparison between the groups was performed.

Results: A total of 945 patients were included (59.6% without diabetes, 27% with diabetes, and 13.4% with stress hyperglycemia). Fifty-five-point three percent required intensive care unit management, with a higher need in patients with stress hyperglycemia (89.8%) and diabetes (67.1%), with no difference between these groups (p = 0.249). We identified a higher probability of death in the group with stress hyperglycemia versus the one without diabetes (adjusted OR = 8.12; 95% CI: 5.12-12.88; p < 0.01). Frequency of acute respiratory distress syndrome, need for invasive mechanical ventilation, use of vasopressors and inotropes, need for de novo renal replacement therapy, and mortality was higher in patients with metabolic alterations (diabetes and stress hyperglycemia).

Conclusions: Diabetes and stress hyperglycemia were associated with worse clinical outcomes and mortality in patients with COVID-19. These patients should be identified early and considered them high risk at the COVID-19 diagnosis to mitigate adverse outcomes.

引言糖尿病和应激性高血糖与 SARS-CoV-2 感染者较差的临床预后有关,并且有可能导致严重疾病:评估三组 SARS-CoV-2 感染者(有糖尿病、无糖尿病和应激性高血糖)的临床预后:在哥伦比亚卡利市开展了一项回顾性队列研究。研究对象包括 2020 年 3 月至 2021 年 12 月期间在急诊室、住院部或重症监护室接受治疗的确诊感染 SARS-CoV-2 的 18 岁及以上患者。免疫力低下的患者和孕妇除外。患者分为三组:无糖尿病组、糖尿病组和应激性高血糖组。各组之间进行比较:结果:共纳入了 945 名患者(59.6% 无糖尿病,27% 有糖尿病,13.4% 有应激性高血糖)。55.3%的患者需要接受重症监护,其中应激性高血糖患者(89.8%)和糖尿病患者(67.1%)的需求更高,但这两组患者之间没有差异(P = 0.249)。我们发现,应激性高血糖组与非糖尿病组相比,死亡概率更高(调整后 OR = 8.12;95% CI:5.12-12.88;p <0.01)。有代谢改变(糖尿病和应激性高血糖)的患者发生急性呼吸窘迫综合征、需要有创机械通气、使用血管加压药和肌注药、需要新的肾脏替代治疗以及死亡的频率更高:结论:糖尿病和应激性高血糖与COVID-19患者较差的临床预后和死亡率有关。结论:糖尿病和应激性高血糖与COVID-19患者更差的临床预后和死亡率有关。在诊断COVID-19时,应及早发现这些患者并将其视为高危人群,以减轻不良预后。
{"title":"Clinical outcomes in patients with diabetes and stress hyperglycemia that developed SARS-CoV-2 infection","authors":"Karen M Fériz-Bonelo, María B Iriarte-Durán, Oscar Giraldo, Luis G Parra-Lara, Veline Martínez, María A Urbano, Guillermo Guzmán","doi":"10.7705/biomedica.7095","DOIUrl":"10.7705/biomedica.7095","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes and stress hyperglycemia have been related with poorer clinical outcomes in patients infected by SARS-CoV-2 and at risk for severe disease.</p><p><strong>Objective: </strong>To evaluate clinical outcomes in three groups of patients (with diabetes, without diabetes and with stress hyperglycemia) with SARS-CoV-2 infection.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted in Cali (Colombia). We included patients 18 years old or older with a diagnosis of SARS-CoV-2 infection, managed in the emergency room, hospitalization, or intensive care unit between March 2020 and December 2021. Immunocompromised patients and pregnant women were excluded. Patients were classified into three groups: without diabetes, with diabetes, and with stress hyperglycemia. A comparison between the groups was performed.</p><p><strong>Results: </strong>A total of 945 patients were included (59.6% without diabetes, 27% with diabetes, and 13.4% with stress hyperglycemia). Fifty-five-point three percent required intensive care unit management, with a higher need in patients with stress hyperglycemia (89.8%) and diabetes (67.1%), with no difference between these groups (p = 0.249). We identified a higher probability of death in the group with stress hyperglycemia versus the one without diabetes (adjusted OR = 8.12; 95% CI: 5.12-12.88; p < 0.01). Frequency of acute respiratory distress syndrome, need for invasive mechanical ventilation, use of vasopressors and inotropes, need for de novo renal replacement therapy, and mortality was higher in patients with metabolic alterations (diabetes and stress hyperglycemia).</p><p><strong>Conclusions: </strong>Diabetes and stress hyperglycemia were associated with worse clinical outcomes and mortality in patients with COVID-19. These patients should be identified early and considered them high risk at the COVID-19 diagnosis to mitigate adverse outcomes.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"73-88"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating zinc levels and cardiometabolic risk-related variables in adults [循环锌水平与成人心脏代谢风险相关变量]。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.6882
Milton Fabián Suárez-Ortegón, Alejandra Arbeláez, José Guillermo Ortega-Ávila, Mildrey Mosquera

Introduction. Altered serum zinc levels, lower and higher than values in healthy controls, have been observed in individuals affected by non-communicable chronic diseases. However, to date, studies describing potential determinants of zinc levels in general populations free of chronic diseases appear to be limited.Objective. To evaluate whether nutrient intake, biochemical and clinical measures, lifestyle, and family history of cardio-metabolic diseases are independently associated with zinc levels in apparently healthy individuals.Materials and methods. We evaluated 239 healthy subjects. Serum zinc was measured via flame atomic absorption spectrometry, and the remaining biochemical markers were assessed using enzymatic colorimetric methods. Standard techniques were employed to quantify waist circumference, height, and weight. Body fat was measured via bioimpedance, and blood pressure was measured using digital sphygmomanometers. We applied a survey to record the personal and family history of non-communicable chronic diseases, and nutrient intake was estimated using the 24-hour recall method.Results. Women had lower serum zinc levels than men. In multivariate analyzes, total fat intake (β = -0.15; standard error = 0.03; p < 0.001), plasma log-triglycerides (β = -10.18; standard error = 3.9; p = 0.010), and female gender (β = -6.81; standard error = 3.3; p = 0.043) were significant predictors for serum zinc levels. Zinc intake was not significantly related to serum zinc in univariate and multivariate analyses.Conclusions. Variables related to cardiometabolic risk, such as plasma triglyceride levels and total fat intake, were associated with serum zinc levels in individuals without a diagnosis of chronic or infectious/inflammatory diseases. Further studies are required to confirm our findings and to evaluate possible biological mechanisms for these relationships.

导言。据观察,慢性非传染性疾病患者的血清锌水平会发生变化,或高或低。然而,有关无慢性疾病人群血清锌决定因素的信息却非常有限。 目的:评估表面健康人群的营养摄入、生化和临床指标、生活方式和心脏代谢疾病家族史是否与锌水平独立相关。材料与方法共对 239 名健康受试者进行了评估。血清锌采用火焰原子吸收光谱法测定,所有其他生化指标采用酶比色法测定。人体测量采用标准技术。通过调查记录了个人和家族病史,并通过 24 小时回忆估算了营养素摄入量。在多变量分析中,总脂肪摄入量(β = -0.15;标准误差 = 0.03;P 结论:女性的血清锌含量低于男性:在未确诊慢性病或感染性炎症的人群中,甘油三酯水平和总脂肪摄入量等与心脏代谢风险相关的变量与锌水平有关。需要进一步研究来证实这些发现,并评估这些关系的可能生物机制。
{"title":"Circulating zinc levels and cardiometabolic risk-related variables in adults","authors":"Milton Fabián Suárez-Ortegón, Alejandra Arbeláez, José Guillermo Ortega-Ávila, Mildrey Mosquera","doi":"10.7705/biomedica.6882","DOIUrl":"10.7705/biomedica.6882","url":null,"abstract":"<p><p>Introduction. Altered serum zinc levels, lower and higher than values in healthy controls, have been observed in individuals affected by non-communicable chronic diseases. However, to date, studies describing potential determinants of zinc levels in general populations free of chronic diseases appear to be limited.\u0000Objective. To evaluate whether nutrient intake, biochemical and clinical measures, lifestyle, and family history of cardio-metabolic diseases are independently associated with zinc levels in apparently healthy individuals.\u0000Materials and methods. We evaluated 239 healthy subjects. Serum zinc was measured via flame atomic absorption spectrometry, and the remaining biochemical markers were assessed using enzymatic colorimetric methods. Standard techniques were employed to quantify waist circumference, height, and weight. Body fat was measured via bioimpedance, and blood pressure was measured using digital sphygmomanometers. We applied a survey to record the personal and family history of non-communicable chronic diseases, and nutrient intake was estimated using the 24-hour recall method.\u0000Results. Women had lower serum zinc levels than men. In multivariate analyzes, total fat intake (β = -0.15; standard error = 0.03; p < 0.001), plasma log-triglycerides (β = -10.18; standard error = 3.9; p = 0.010), and female gender (β = -6.81; standard error = 3.3; p = 0.043) were significant predictors for serum zinc levels. Zinc intake was not significantly related to serum zinc in univariate and multivariate analyses.\u0000Conclusions. Variables related to cardiometabolic risk, such as plasma triglyceride levels and total fat intake, were associated with serum zinc levels in individuals without a diagnosis of chronic or infectious/inflammatory diseases. Further studies are required to confirm our findings and to evaluate possible biological mechanisms for these relationships.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"63-72"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aducanumab: A look two years after its approval [阿杜单抗:获批两年后的观察]。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.6967
Astrid Torres, Loida Camargo, Norman López

Alzheimer’s disease is the leading cause of dementia worldwide and a critical public health problem. While deaths from cardiovascular diseases have decreased, those attributed to Alzheimer’s disease have increased in recent years with no curative treatment to date. In this context, effective treatment development has become a global priority. Aducanumab is a human anti-amyloid β monoclonal antibody approved by the FDA in June 2021 for the treatment of Alzheimer’s disease but failed to show the expected clinical efficacy in phase III trials.This review analyzes the history of its controversial acceptance, implications, and prospects for future treatment.

阿尔茨海默病是全球痴呆症的主要病因,也是一个重大的公共卫生问题。虽然心血管疾病导致的死亡人数有所下降,但近年来阿尔茨海默病导致的死亡人数却在增加,而且迄今为止还没有任何治疗方法。因此,开发有效的治疗方法已成为全球的当务之急。Aducanumab 是一种人类抗淀粉样蛋白 β-淀粉样蛋白单克隆抗体,于 2021 年 6 月被美国 FDA 批准用于治疗阿尔茨海默病,但在 III 期试验中未取得预期的临床疗效。本综述讨论了该药物备受争议的接受历史、影响以及未来治疗的前景。
{"title":"Aducanumab: A look two years after its approval","authors":"Astrid Torres, Loida Camargo, Norman López","doi":"10.7705/biomedica.6967","DOIUrl":"10.7705/biomedica.6967","url":null,"abstract":"<p><p>Alzheimer’s disease is the leading cause of dementia worldwide and a critical public health problem. While deaths from cardiovascular diseases have decreased, those attributed to Alzheimer’s disease have increased in recent years with no curative treatment to date. In this context, effective treatment development has become a global priority. Aducanumab is a human anti-amyloid β monoclonal antibody approved by the FDA in June 2021 for the treatment of Alzheimer’s disease but failed to show the expected clinical efficacy in phase III trials.\u0000This review analyzes the history of its controversial acceptance, implications, and prospects for future treatment.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycemic control and study of lipid and bone metabolism in type 1 diabetic children [1 型糖尿病儿童的血糖控制及脂质和骨骼代谢研究]。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7132
Pilar Calmarza, Rasha Isabel Pérez-Ajami, Carlos Prieto-López, Alba Gallego-Royo, Celia García-Carro, Graciela María Lou-Francés

Introduction. Type 1 diabetes mellitus is considered one of the most common chronic diseases of childhood. It is a high-risk factor for developing early cardiovascular disease and it also affects bone health.Objective. To describe demographic characteristics and biochemical parameters of a population of children with type 1 diabetes, evaluated in the pediatric diabetes unit of a tertiary Spanish hospital.Materials and methods. In this retrospective study, we determined metabolic, lipid, and bone parameters in 124 children with type 1 diabetes who were monitored in the pediatric diabetes unit of the Hospital Universitario Miguel Servet in Zaragoza (Spain) from May 2020 to July 2021.Results. Children with type 1 diabetes have worse metabolic control of the disease at puberty, but their lipid control is considered acceptable. We found an inverse correlation between bone formation markers and disease duration, as well as with metabolic control.Conclusion. Bone formation markers are inversely correlated with the percentage of glycated hemoglobin and diabetes evolution time. Patients’ lipid and bone profiles are more favorable when metabolic control of the disease is achieved.

导言1 型糖尿病被认为是儿童时期最常见的慢性疾病之一。它是罹患早期心血管疾病的主要风险因素,也会影响骨骼健康。目的描述西班牙一家三甲医院儿科糖尿病科所监护的 1 型糖尿病患儿的人口统计学特征和生化指标。材料和方法。在这项回顾性研究中,对萨拉戈萨米格尔-塞尔维特大学医院儿科糖尿病科 2020 年 5 月至 2021 年 7 月期间监测的 124 名 1 型糖尿病患儿的代谢、血脂和骨骼控制参数进行了测定。结果1型糖尿病患儿在青春期的代谢控制较差,但血脂控制尚可。骨形成指标与疾病演变时间以及代谢控制呈反向关系。结论骨形成指标与糖化血红蛋白的百分比和糖尿病的病程成反比。在这些患者中,如果代谢控制良好,则血脂和骨质状况更佳。
{"title":"Glycemic control and study of lipid and bone metabolism in type 1 diabetic children","authors":"Pilar Calmarza, Rasha Isabel Pérez-Ajami, Carlos Prieto-López, Alba Gallego-Royo, Celia García-Carro, Graciela María Lou-Francés","doi":"10.7705/biomedica.7132","DOIUrl":"10.7705/biomedica.7132","url":null,"abstract":"<p><p>Introduction. Type 1 diabetes mellitus is considered one of the most common chronic diseases of childhood. It is a high-risk factor for developing early cardiovascular disease and it also affects bone health.\u0000Objective. To describe demographic characteristics and biochemical parameters of a population of children with type 1 diabetes, evaluated in the pediatric diabetes unit of a tertiary Spanish hospital.\u0000Materials and methods. In this retrospective study, we determined metabolic, lipid, and bone parameters in 124 children with type 1 diabetes who were monitored in the pediatric diabetes unit of the Hospital Universitario Miguel Servet in Zaragoza (Spain) from May 2020 to July 2021.\u0000Results. Children with type 1 diabetes have worse metabolic control of the disease at puberty, but their lipid control is considered acceptable. We found an inverse correlation between bone formation markers and disease duration, as well as with metabolic control.\u0000Conclusion. Bone formation markers are inversely correlated with the percentage of glycated hemoglobin and diabetes evolution time. Patients’ lipid and bone profiles are more favorable when metabolic control of the disease is achieved.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"171-181"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Hybribio-H13 and Hybrid Capture® 2 human papillomavirus tests for detection of CIN2+ and CIN3. Hybribio-H13 和 Hybrid Capture® 2 人类乳头瘤病毒检测试剂盒在检测 CIN2+ 和 CIN3 方面的比较。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7061
María Cecilia Agudelo, Edmundo Torres-González, Samuel Agudelo, Arianis Tatiana Ramírez, Kelly Melisa Castañeda, Connor J Kinslow, María Rodríguez-Herrera, Lisa Garland, Yi Xie, Carlos Alberto Orozco, Mark Stoler, Michael Dean, Gloria Inés Sánchez

Introduction: Low-cost, accurate high-risk HPV tests are needed for cervical cancer screening in limited-resource settings.

Objective: To compare the performance of the low-cost Hybribio-H13 test with the Hybrid Capture® 2 to detect cervical intraepithelial neoplasia grade 2 or 3 (CIN2 and CIN3).

Materials and methods: Archived baseline samples tested by the Hybrid Capture® 2 from women of the ASCUS-COL trial, aged 20 to 69 years, with biopsy-colposcopy directed diagnosis of CIN2+ (n = 143), CIN3+ (n = 51), and < CIN2 (n = 632) were blindly tested by the Hybribio-H13 test.

Results: The relative sensitivity of the Hybribio-H13 test versus the Hybrid Capture® 2 for detecting CIN2+ was 0.89 (90% CI = 0,80-0,98; NIT = 0,66), and for CIN3+ was 0,92 (90% CI = 0,85-0,98; NIT = 0,35). Relative specificity was 1.19 (90% CI = 1.05-1.33; NIT <0.00001). In the analysis restricted to women older than 30 years, the relative sensitivity of the Hybribio-H13 for CIN3+ was marginally below unity (ratio = 0.97; 90% CI = 0.95-0.99), and the specificity remained higher than the Hybrid Capture® 2 test.

Conclusion: The Hybribio-H13 test was as specific as the Hybrid Capture® 2 for detecting CIN2+ or CIN3+ but less sensitive. Considering these results and the young age of the population recruited for screening because of ASCUS cytology, we suggest our results warrant the evaluation of the Hybribio-H13 for screening cervical cancer, especially in the evaluated population.

导言:在资源有限的环境中,宫颈癌筛查需要低成本、准确的高危HPV检测:比较低成本的 Hybribio-H13 检测试剂盒与 Hybrid Capture® 2 检测 2 级或 3 级宫颈上皮内瘤变(CIN2 和 CIN3)的性能:用Hybrid Capture® 2检测的基线样本来自ASCUS-COL试验的妇女,年龄在20-69岁之间,活检-阴道镜检查诊断为CIN2+(143人)、CIN3+(51人)和< CIN2(632人):Hybribio-H13检验与Hybrid Capture® 2相比,检测CIN2+的相对灵敏度为0.89(90% CI = 0.80-0.98;NIT = 0.66),检测CIN3+的相对灵敏度为0.92(90% CI = 0.85-0.98;NIT = 0.35)。相对特异性为 1.19(90% CI = 1.05-1.33;NIT 结论):在检测 CIN2+ 或 CIN3+ 方面,Hybribio-H13 检测仪与 Hybrid Capture® 2 检测仪的特异性相同,但灵敏度较低。考虑到这些结果以及因 ASCUS 细胞学结果而被招募进行筛查的人群年龄较小,我们建议对 Hybribio-H13 进行评估,以筛查宫颈癌,尤其是在被评估人群中。
{"title":"Comparison of Hybribio-H13 and Hybrid Capture® 2 human papillomavirus tests for detection of CIN2+ and CIN3.","authors":"María Cecilia Agudelo, Edmundo Torres-González, Samuel Agudelo, Arianis Tatiana Ramírez, Kelly Melisa Castañeda, Connor J Kinslow, María Rodríguez-Herrera, Lisa Garland, Yi Xie, Carlos Alberto Orozco, Mark Stoler, Michael Dean, Gloria Inés Sánchez","doi":"10.7705/biomedica.7061","DOIUrl":"10.7705/biomedica.7061","url":null,"abstract":"<p><strong>Introduction: </strong>Low-cost, accurate high-risk HPV tests are needed for cervical cancer screening in limited-resource settings.</p><p><strong>Objective: </strong>To compare the performance of the low-cost Hybribio-H13 test with the Hybrid Capture® 2 to detect cervical intraepithelial neoplasia grade 2 or 3 (CIN2 and CIN3).</p><p><strong>Materials and methods: </strong>Archived baseline samples tested by the Hybrid Capture® 2 from women of the ASCUS-COL trial, aged 20 to 69 years, with biopsy-colposcopy directed diagnosis of CIN2+ (n = 143), CIN3+ (n = 51), and < CIN2 (n = 632) were blindly tested by the Hybribio-H13 test.</p><p><strong>Results: </strong>The relative sensitivity of the Hybribio-H13 test versus the Hybrid Capture® 2 for detecting CIN2+ was 0.89 (90% CI = 0,80-0,98; NIT = 0,66), and for CIN3+ was 0,92 (90% CI = 0,85-0,98; NIT = 0,35). Relative specificity was 1.19 (90% CI = 1.05-1.33; NIT <0.00001). In the analysis restricted to women older than 30 years, the relative sensitivity of the Hybribio-H13 for CIN3+ was marginally below unity (ratio = 0.97; 90% CI = 0.95-0.99), and the specificity remained higher than the Hybrid Capture® 2 test.</p><p><strong>Conclusion: </strong>The Hybribio-H13 test was as specific as the Hybrid Capture® 2 for detecting CIN2+ or CIN3+ but less sensitive. Considering these results and the young age of the population recruited for screening because of ASCUS cytology, we suggest our results warrant the evaluation of the Hybribio-H13 for screening cervical cancer, especially in the evaluated population.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"101-109"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge domains and emerging trends in non-invasive brain stimulation: A bibliometric analysis via CiteSpace 无创脑部刺激的知识领域和新兴趋势:通过 CiteSpace 进行文献计量分析。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7040
Inmaculada Ruiz-López, Desirée Victoria-Montesinos, Juan Martínez-Fuentes

Introduction: In recent decades, new non-invasive brain stimulation techniques and protocols have been developed, such as transcranial magnetic stimulation and transcranial direct current stimulation.

Objective: To identify and visualize the intellectual structure of non-invasive brain stimulation through document co-citation analysis.

Materials and methods: We analyzed 30,854 Web of Science-indexed manuscripts and their 1,615,692 references regarding non-invasive brain stimulation, all published from 1988 to 2022. We drew a document co-citation network map using CiteSpace software.

Results: The most productive journal was Clinical Neurophysiology. The most published institution was the University College London, and the country with the most reports was the USA. The most productive author was Alvaro Pascual-Leone and the most cited author in the non-invasive brain stimulation field was J. C. Rothwell. In addition, the most cited study was that of Rossi et al. (2009). The safe application of non-invasive brain stimulation techniques and their effects on motor or executive functions is an emerging trend in this research area.

Conclusions: The current investigation displayed a quantitative scientometric approach and delved into the advancement of non-invasive brain stimulation research by examining the references published in this domain. These findings can be valuable for professionals to picture the patterns of recognition and emerging directions in the field.

简介:近几十年来,经颅磁刺激和经颅直流电刺激等新的无创脑刺激技术和方案不断发展:近几十年来,经颅磁刺激和经颅直流电刺激等新的非侵入性脑刺激技术和方案不断涌现:材料与方法:我们分析了 30,854 篇 Web of Science 索引的手稿及其 1,615,692 篇有关无创脑部刺激的参考文献,这些文献均发表于 1988 年至 2022 年期间。我们使用 CiteSpace 软件绘制了文献共引网络图:成果最多的期刊是《临床神经生理学》。发表论文最多的机构是伦敦大学学院,发表报告最多的国家是美国。高产作者是 Alvaro Pascual-Leone,在无创脑刺激领域被引用最多的作者是 J. C. Rothwell。此外,被引用最多的研究是 Rossi 等人(2009 年)的研究。非侵入性脑刺激技术的安全应用及其对运动或执行功能的影响是这一研究领域的新兴趋势:目前的调查采用了定量科学计量学方法,通过研究该领域发表的参考文献,深入探讨了无创脑部刺激研究的进展。这些发现对专业人士了解该领域的认知模式和新兴方向很有价值。
{"title":"Knowledge domains and emerging trends in non-invasive brain stimulation: A bibliometric analysis via CiteSpace","authors":"Inmaculada Ruiz-López, Desirée Victoria-Montesinos, Juan Martínez-Fuentes","doi":"10.7705/biomedica.7040","DOIUrl":"10.7705/biomedica.7040","url":null,"abstract":"<p><strong>Introduction: </strong>In recent decades, new non-invasive brain stimulation techniques and protocols have been developed, such as transcranial magnetic stimulation and transcranial direct current stimulation.</p><p><strong>Objective: </strong>To identify and visualize the intellectual structure of non-invasive brain stimulation through document co-citation analysis.</p><p><strong>Materials and methods: </strong>We analyzed 30,854 Web of Science-indexed manuscripts and their 1,615,692 references regarding non-invasive brain stimulation, all published from 1988 to 2022. We drew a document co-citation network map using CiteSpace software.</p><p><strong>Results: </strong>The most productive journal was Clinical Neurophysiology. The most published institution was the University College London, and the country with the most reports was the USA. The most productive author was Alvaro Pascual-Leone and the most cited author in the non-invasive brain stimulation field was J. C. Rothwell. In addition, the most cited study was that of Rossi et al. (2009). The safe application of non-invasive brain stimulation techniques and their effects on motor or executive functions is an emerging trend in this research area.</p><p><strong>Conclusions: </strong>The current investigation displayed a quantitative scientometric approach and delved into the advancement of non-invasive brain stimulation research by examining the references published in this domain. These findings can be valuable for professionals to picture the patterns of recognition and emerging directions in the field.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"139-150"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador [在免疫性血小板减少症中使用 romiplostim:昆卡(厄瓜多尔)的经验]。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7059
Héctor Chiang-Wong, Patricio González-Saldaña

Introduction. The international consensus and the American Society of Hematology guidelines from 2019 established thrombopoietin analogues as the second-line therapy for primary immune thrombocytopenia cases.Objectives. To describe romiplostim usefulness in patients with immune thrombocytopenia in a third-level hospital in Cuenca, Ecuador.Materials and methods. We conducted a descriptive and retrospective study in patients with immune thrombocytopenia treated with romiplostim. We evaluated the following variables: age, gender, previous therapies to romiplostim, dose, frequency, complications, change of thrombopoietin analogue, and treatment discontinuation.Results. We included 21 patients with immune thrombocytopenia treated with romiplostim, with a median age of 49 years. All patients received corticosteroids as first-line treatment. Three patients required longer administration intervals (over a week), with weekly doses lower than those recommended (< 1 μg/kg). Due to lack of efficacy, six patients replaced elthrombopag with romiplostim. Of the total, three suffered thrombotic complications: two had portal venous thrombosis, and one had pulmonary thromboembolism; five of the patients discontinued romiplostim scheme without resuming it.Conclusions. Romiplostim constitutes a convenient second-line therapy in immune thrombocytopenia. Despite the small sample size, romiplostim early use can minimize toxicities and infectious risks.

导言。国际共识和美国血液学会 2019 年指南将促血小板生成素类似物确定为治疗原发性免疫性血小板减少症的二线药物。目的:描述昆卡(厄瓜多尔)一家三甲医院在免疫性血小板减少症患者中使用romiplostim的情况。材料与方法对免疫性血小板减少症患者进行了一项描述性和回顾性研究。结果:21 名免疫性血小板减少症患者接受了罗米诺司汀治疗,中位年龄为 49 岁。所有患者都接受了皮质类固醇作为一线疗法。其中三人需要的间隔时间长于每周一次,每周剂量低于推荐剂量(< 1 μg/kg)。由于疗效不佳,有六名患者的艾曲波帕治疗被罗米波司汀取代。三名患者出现了血栓并发症:两名患者出现门静脉血栓,一名患者出现肺血栓栓塞。5名患者停止了罗米波司汀治疗,无需重新开始治疗:罗米波司汀是治疗原发性免疫性血小板减少症的二线疗法。结论:罗米波司汀是治疗原发性免疫性血小板减少症的二线疗法,尽管样本量较小,但早期用药可将毒性和感染风险降至最低。
{"title":"Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador","authors":"Héctor Chiang-Wong, Patricio González-Saldaña","doi":"10.7705/biomedica.7059","DOIUrl":"10.7705/biomedica.7059","url":null,"abstract":"<p><p>Introduction. The international consensus and the American Society of Hematology guidelines from 2019 established thrombopoietin analogues as the second-line therapy for primary immune thrombocytopenia cases.\u0000Objectives. To describe romiplostim usefulness in patients with immune thrombocytopenia in a third-level hospital in Cuenca, Ecuador.\u0000Materials and methods. We conducted a descriptive and retrospective study in patients with immune thrombocytopenia treated with romiplostim. We evaluated the following variables: age, gender, previous therapies to romiplostim, dose, frequency, complications, change of thrombopoietin analogue, and treatment discontinuation.\u0000Results. We included 21 patients with immune thrombocytopenia treated with romiplostim, with a median age of 49 years. All patients received corticosteroids as first-line treatment. Three patients required longer administration intervals (over a week), with weekly doses lower than those recommended (< 1 μg/kg). Due to lack of efficacy, six patients replaced elthrombopag with romiplostim. Of the total, three suffered thrombotic complications: two had portal venous thrombosis, and one had pulmonary thromboembolism; five of the patients discontinued romiplostim scheme without resuming it.\u0000Conclusions. Romiplostim constitutes a convenient second-line therapy in immune thrombocytopenia. Despite the small sample size, romiplostim early use can minimize toxicities and infectious risks.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"198-204"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke associated with primary membranous nephropathy in a young adult: Case report 一名年轻成年人中风并发原发性膜性肾病:病例报告。
Pub Date : 2024-05-31 DOI: 10.7705/biomedica.7117
Juan Pablo Morales

Introduction: Stroke in young individuals is becoming increasingly prevalent worldwide. Its causes can vary widely, so a thorough investigation by a multidisciplinary team is needed. Pinpointing the precise underlying pathology responsible for the stroke yields benefits for patients, particularly in recurrent events.

Case presentation: A 38-year-old man presented to the emergency department with symptoms suggestive of stroke, including right hemiparesis, dysarthria, ataxic gait, and right central facial palsy. The brain magnetic resonance image revealed an ischemic lesion located in the left basal ganglia and near the corona radiata. Following an extensive workup, a diagnosis of nephrotic was reached. Histopathology and the exclusion of secondary causes confirmed primary membranous nephropathy as the underlying condition. The patient underwent treatment tailored to address the specific glomerulopathy, along with anticoagulation therapy and immunosuppression as per current guidelines. Subsequent assessments showed stabilization of renal function, resolution of the edema, and the absence of new thromboembolic events during follow-up.

Conclusion: The nephrotic syndrome should be recognized as a potential underlying cause of stroke in young patients and, therefore, it should be included in the differential diagnosis during the evaluation of patients with coagulopathies. Nephrotic syndrome screening may be done by conducting a simple urinalysis readily available in most healthcare facilities. This underlines the importance of considering renal pathology in the assessment of stroke etiologies, especially when coagulation abnormalities are present.

简介全世界年轻人中风的发病率越来越高。其病因千差万别,因此需要由多学科团队进行彻底检查。准确找出导致中风的潜在病理原因可为患者带来益处,尤其是对复发患者:一名 38 岁的男子因右侧偏瘫、构音障碍、共济失调步态和右侧中枢性面瘫等提示卒中的症状到急诊科就诊。脑磁共振图像显示,缺血性病变位于左侧基底节和放射冠附近。经过全面检查,确诊为肾病。经组织病理学检查和排除继发性病因后,确认原发性膜性肾病是其根本病因。患者接受了针对特定肾小球病变的治疗,并按照现行指南接受了抗凝治疗和免疫抑制。随后的评估显示,患者的肾功能趋于稳定,水肿消退,随访期间也没有发生新的血栓栓塞事件:结论:应认识到肾病综合征是年轻患者中风的潜在病因,因此在评估凝血病患者时应将其纳入鉴别诊断。肾病综合征的筛查可通过大多数医疗机构都可提供的简单尿液分析进行。这强调了在评估卒中病因时考虑肾脏病理的重要性,尤其是在出现凝血异常时。
{"title":"Stroke associated with primary membranous nephropathy in a young adult: Case report","authors":"Juan Pablo Morales","doi":"10.7705/biomedica.7117","DOIUrl":"10.7705/biomedica.7117","url":null,"abstract":"<p><strong>Introduction: </strong>Stroke in young individuals is becoming increasingly prevalent worldwide. Its causes can vary widely, so a thorough investigation by a multidisciplinary team is needed. Pinpointing the precise underlying pathology responsible for the stroke yields benefits for patients, particularly in recurrent events.</p><p><strong>Case presentation: </strong>A 38-year-old man presented to the emergency department with symptoms suggestive of stroke, including right hemiparesis, dysarthria, ataxic gait, and right central facial palsy. The brain magnetic resonance image revealed an ischemic lesion located in the left basal ganglia and near the corona radiata. Following an extensive workup, a diagnosis of nephrotic was reached. Histopathology and the exclusion of secondary causes confirmed primary membranous nephropathy as the underlying condition. The patient underwent treatment tailored to address the specific glomerulopathy, along with anticoagulation therapy and immunosuppression as per current guidelines. Subsequent assessments showed stabilization of renal function, resolution of the edema, and the absence of new thromboembolic events during follow-up.</p><p><strong>Conclusion: </strong>The nephrotic syndrome should be recognized as a potential underlying cause of stroke in young patients and, therefore, it should be included in the differential diagnosis during the evaluation of patients with coagulopathies. Nephrotic syndrome screening may be done by conducting a simple urinalysis readily available in most healthcare facilities. This underlines the importance of considering renal pathology in the assessment of stroke etiologies, especially when coagulation abnormalities are present.</p>","PeriodicalId":101322,"journal":{"name":"Biomedica : revista del Instituto Nacional de Salud","volume":"44 Sp. 1","pages":"11-17"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Biomedica : revista del Instituto Nacional de Salud
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1